Publications in VIVO

Co-author Network

Eileen M Boyle, MD, MSc, PhD

Person

Positions

Consultant, University College London
Other, University College London

Clinical Disciplines

Hematology

Publications
Other
View All

Selected Publications

article
1. Challenges in designing and running smouldering myeloma interventional clinical trials. eJHaem. 2024
2. Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research. 2024
3. Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma. Clinical Cancer Research. 2023
4. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023
5. Bartonellosis mimicking post-transplant lymphoproliferative diseases. Nephrology Dialysis Transplantation. 2022
6. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications. 2022
7. Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow. British Journal of Haematology. 2022
8. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery. 2022
9. Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer Journal. 2022
10. Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma.. Clinical lymphoma, myeloma & leukemia. 2021
11. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.. Haematologica. 2021
12. High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology. 2021
13. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia. 2021
14. PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine. 2021
15. The evolving role and utility of off-label drug use in multiple myeloma. Exploration of Targeted Anti-tumor Therapy. 2021
16. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.. Nature communications. 2021
17. Accelerated single cell seeding in relapsed multiple myeloma.. Nature communications. 2020
18. Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.. Leukemia research reports. 2020
19. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research. 2020
20. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.. Blood cancer journal. 2020
21. Monitoring minimal residual disease in the bone marrow using next generation sequencing.. Best practice & research. Clinical haematology. 2020
22. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.. European journal of haematology. 2020
23. Reconstructing the evolutionary history of multiple myeloma.. Best practice & research. Clinical haematology. 2020
24. Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discovery. 2020
25. Revealing the impact of structural variants in multiple myeloma.. Blood cancer discovery. 2020
26. TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use.. BMC bioinformatics. 2020
27. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial. British Journal of Haematology. 2019
28. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.. Leukemia. 2019
29. Evaluation of the Relevance of Surgery in Patients with Multiple Myeloma Harboring Symptomatic Spinal Involvement: A Retrospective Case Series. World Neurosurgery. 2018
30. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018
31. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.. Blood. 2017
32. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.. Leukemia & lymphoma. 2017
33. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.. Neurology. 2017
34. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.. Leukemia. 2017
35. Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma.. Haematologica. 2017
36. BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.. Oncotarget. 2016
37. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
38. IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
39. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.. Blood. 2016
40. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016
41. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.. Genes, chromosomes & cancer. 2015
42. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.. Nature communications. 2015
43. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.. British journal of haematology. 2015
44. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.. Blood. 2015
45. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015
46. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.. Expert opinion on drug safety. 2015
47. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.. Cancer cell. 2014
48. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.. Cancer. 2014
49. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.. British journal of haematology. 2014
50. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.. Blood cancer journal. 2014
51. Understanding the multiple biological aspects leading to myeloma.. Haematologica. 2014
52. Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 2013
53. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.. Thrombosis and haemostasis. 2013
54. Early coagulopathy in trauma patients: an on-scene and hospital admission study.. Injury. 2012
55. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012
56. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.. Expert review of hematology. 2012
57. Prognostic value of PINI index in patients with multiple myeloma.. European journal of haematology. 2012
58. Novel M-component based biomarkers in Waldenström's macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 2011
59. Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.. Current oncology reports. 2011
document